IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Mihir Metkar
Application No.: 17/000,215
Confirmation No.: 4663
Filed: August 21, 2020
For: CORONAVIRUS RNA VACCINES
Examiner: J. J. Zara
Art Unit: 1635

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Dear Commissioner:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, the undersigned requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.

No fee or certification is required.

PART II: Information Cited

The undersigned hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The undersigned hereby makes the following additional information of record in the above-identified application.

9433840.1
Pursuant to 37 C.F.R. § 1.56, Applicants disclose that their collaborators at the National Institutes of Health submitted John Mascola, M.D.; Barney Graham, M.D., Ph.D.; and Kizzmekia Corbett, Ph.D. to Applicants as additional co-inventors of this patent application. However, Applicants have reached the good-faith determination that these individuals did not co-invent the mRNAs and mRNA compositions claimed in the present application.

The undersigned would like to bring to the Examiner’s attention the following co-pending applications that may contain subject matter related to this application:

<table>
<thead>
<tr>
<th>Serial No.</th>
<th>Filing Date</th>
<th>Inventor(s)</th>
<th>Docket No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>*16/036,318</td>
<td>07-16-2018</td>
<td>Ciaramella et al.</td>
<td>M1378.70002US05</td>
</tr>
<tr>
<td>*16/144,394</td>
<td>09-27-2018</td>
<td>Ciaramella et al.</td>
<td>M1378.70002US07</td>
</tr>
<tr>
<td>*17/204,801</td>
<td>03-17-2021</td>
<td>Ciaramella et al.</td>
<td>M1378.70002US11</td>
</tr>
<tr>
<td>*16/853,973</td>
<td>04-21-2020</td>
<td>Ciaramella et al.</td>
<td>M1378.70030US07</td>
</tr>
<tr>
<td>*16/850,519</td>
<td>04-16-2020</td>
<td>Ciaramella et al.</td>
<td>M1378.70030US08</td>
</tr>
</tbody>
</table>

*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

The undersigned would like to bring to the Examiner’s attention the enclosed search report or other communication from a corresponding or related International or Foreign National Application:

<table>
<thead>
<tr>
<th>Serial No.</th>
<th>Date of Mailing</th>
<th>Type(s) of Communication</th>
<th>Docket No.</th>
</tr>
</thead>
</table>

**PART III: Remarks**

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the United States Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the undersigned makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the undersigned makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, the undersigned makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102, or an admission by Applicant as prior art.

Notwithstanding any statements by the undersigned, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.
An early and favorable action is hereby requested.

The Director is hereby authorized to charge any deficiency or credit any overpayment in the fees occasioned by the filing of this Information Disclosure Statement to our Deposit Account No. 23/2825 under Docket No. M1378.70145US07 from which the undersigned is authorized to draw.

Respectfully submitted,

By: /Helen C. Lockhart/
Helen C. Lockhart
Registration No.: 39,248
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
617.646.8000

Docket No.: M1378.70145US07
Date: July 28, 2021